<DOC>
	<DOCNO>NCT02087579</DOCNO>
	<brief_summary>The purpose study gather information steady-state plasma concentration aripiprazole , olanzapine , quetiapine relevant metabolite , various dose level different time point dose . In addition , comparison capillary drug concentration vs. venous drug concentration perform aripiprazole , olanzapine , paliperidone , quetiapine , risperidone relevant metabolite .</brief_summary>
	<brief_title>Parallel Group , Multiple Dose Pharmacokinetics Study Five Antipsychotic Medications Psychiatric Participants</brief_title>
	<detailed_description>This open-label ( physicians participant know identity assign treatment ) , parallel-group , multiple-dose , multicenter study ass pharmacokinetics ( body medication ) five antipsychotic ( APS ) drug : aripiprazole , olanzapine , paliperidone , quetiapine risperidone psychiatric participant receive stable dos drug treatment disease . Pharmacokinetics data generate venous fingerstick-based capillary plasma concentration drug metabolite . The total number enrol participant study least 265 . Seventy-five participant enrol aripiprazole , olanzapine quetiapine cohort ( group ) , 20 participant enrol paliperidone risperidone cohort . In aripiprazole , olanzapine quetiapine cohort two subgroup . Subgroup one , 20 participant fingerstick capillary + venous blood sample subgroup two , 55 participant venous sample . Paliperidone risperidone cohort subject capillary + venous blood sampling . The study consist screen phase ( within 21 day Day 1 ) follow 3-day observation phase ( Day 1 Day 3 ) . Participants admit study center even Day -1 remain study center discharge Day 3 completion last study-related procedure . During observation phase , administration prior antipsychotic medication continue participant 's usual dose dose schedule , direct observation study staff . There modification participant 's medication study . Safety evaluate throughout study mandatory pharmacogenomic blood sample collect analysis gene may influence exposure APS study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Must clinically stable per investigator 's judgment ( suicidal behavior current significant suicidal judgment base CSSRS rating scale ) No hospitalization exacerbation psychiatric symptom 3 month screen Receiving treatment aripiprazole , olanzapine , paliperidone , quetiapine risperidone , combination study Must body mass index 17 40 kg/m2 ( inclusive ) , body weight less 47 kg Except indication antipsychotic treatment give , generally healthy clinically significant unstable medical problem Must able give inform consent Clinically significant abnormal physical examination , vital sign 12lead ECG screening determine investigator Administering strong inhibitor inducer CYP3A4 , CYP2D6 enzymes , like fluoxetine History current clinically significant ( particularly unstable ) medical illness indication Donated blood blood product substantial loss blood ( 450 mL ) within 3 month Day 1 Lack 6 suitable puncture sit capillary blood draw</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Psychotic Disorders</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depressive Disorder</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Capillary Concentration</keyword>
</DOC>